Your cart is empty.
By Dr Manuel Bauer
As we saw in part 1 of this blog series, liquid chromatography-tandem mass spectrometry (LC-MS/MS) is potentially the new gold standard for therapeutic monitoring of immunosuppressant drugs (ISD). However, for this technology to become widely adopted, the methodology needs to be standardized globally, including addressing bottlenecks both at the pre-analytical stage of sample preparation, and within the process itself. Here we take a look at the top four pitfalls to avoid when implementing LC-MS/MS for ISD monitoring.